GlassScriptPhysician profile
Colin Drolshagen
NPI 1396973541
$3,119.04
in general payments reported to CMS, 2019-2025
33 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $597 · 2022: $170 · 2023: $409 · 2024: $663 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.30 | 2019-2025 | Qulipta, Ubrelvy, Viberzi |
| Pfizer INC. | $369.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $262.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $161.63 | 2019-2024 | Krystexxa |
| Abbott Laboratories | $154.66 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $129.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.50 | 2019-2024 | Ofev |
| Astellas Pharma US INC | $114.50 | 2019-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $91.45 | 2019-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $87.91 | 2024-2025 | Korlym |
| Allergan, INC. | $86.52 | 2020 | |
| Amarin Pharma, INC. | $86.39 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.68 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $78.41 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $77.75 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Exact Sciences Corporation | $74.97 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $67.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.41 | 2019-2025 | Proquad, Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $53.97 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $41.00 | 2024-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $28.56 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.36 | 2019-2020 | |
| Dynavax Technologies Corporation | $23.76 | 2023 | Heplisav-B |
| Dexcom, INC. | $22.35 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $20.53 | 2019 | |
| Optinose US, INC. | $17.33 | 2024 | |
| Ironshore Pharmaceuticals INC. | $17.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.49 | 2019 | |
| Cranial Technologies, INC | $15.77 | 2023 | Doc Band |
| Sumitomo Pharma America, INC. | $14.82 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $14.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2023 | Livalo, Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Drolshagen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.